Subacute adrenal hemorrhage by blunt abdominal contusion during snowboarding (Case report)

The adrenal glands lies deep in the abdomen, seemingly protected from blunt contusion. Wereport a case of a young female presenting left adrenal hemorrhage due to blunt abdominal contusioncaused by a collision during snowboarding, which was successfully treated with embolization

Structural diversity of cancer-related and non-cancer-related prostate-specific antigen

科学研究費補助金研究成果報告書研究種目: 基盤研究(C)研究期間: 2002～2003課題番号: 14571496研究代表者: 吉貴 達寛（滋賀医科大学・医学部・助教授）研究分担者: 若林 賢彦（滋賀医科大学・医学部・講師）研究分担者: 上仁 数義（滋賀医科大学・医学部・助手）研究分担者: 片岡 晃（滋賀医科大学・医学部・助手

Significance and development of Urine uroplakin III mRNA measurement in vesicoureteral reflux

科学研究費補助金研究成果報告書研究種目: 基盤研究(C)研究期間: 2005～2006課題番号: 17591673研究代表者: 上仁 数義（滋賀医科大学・医学部・助手）研究分担者: 吉貴 達寛（滋賀医科大学・医学部・助教授）研究分担者: 成田 充弘（滋賀医科大学・医学部・講師）研究分担者: 影山 進（滋賀医科大学・医学部・助手）研究分担者: 坂野 祐司（滋賀医科大学・医学部・助手

Development of combined tumor markers identified by proteomics in urothelial cancer

科学研究費補助金研究成果報告書研究種目: 基盤研究(C)研究期間: 2004～2005課題番号: 16591593研究代表者: 吉貴 達寛（滋賀医科大学・医学部・助教授）研究分担者: 若林 賢彦（滋賀医科大学・医学部・講師）研究分担者: 金 哲将（滋賀医科大学・医学部・講師）研究分担者: 成田 充弘（滋賀医科大学・医学部・助手）研究分担者: 上仁 数義（滋賀医科大学・医学部・助手

Identification of novel imprinted tumor suppressor gene on 14q for human renal mil carcinoma

科学研究費補助金研究成果報告書研究種目: 基盤研究(B)研究期間: 2005～2007課題番号: 17390438研究代表者: 川上 享弘（滋賀医科大学・医学部・非常勤講師）研究分担者: 岡本 圭生（滋賀医科大学・医学部・講師）研究分担者: 岡田 裕作（滋賀医科大学・医学部・教授）研究分担者: 成田 充弘（滋賀医科大学・医学部・講師）研究分担者: 上仁 数義（滋賀医科大学・医学部・助教）研究分担者: 牛田 博（滋賀医科大学・医学部・助教

Study of human uroplakin in various diseases of urinary tract

科学研究費補助金研究成果報告書研究種目: 基盤研究(C)研究期間: 2001～2002課題番号: 13671648研究代表者: 田中 努（滋賀医科大学・医学部・助手）研究代表者: 片岡 晃（滋賀医科大学・医学部・助手）研究分担者: 岡田 裕作（滋賀医科大学・医学部・教授）研究分担者: 吉貴 達寛（滋賀医科大学・医学部・助教授）研究分担者: 若林 賢彦（滋賀医科大学・医学部・講師）研究分担者: 金 哲将（滋賀医科大学・医学部・講師）研究分担者: 上仁 数義（滋賀医科大学・医学部・助手）研究分担者: 岡本 圭生（滋賀医科大学・医学部・助手

Prognostic nutritional index of early post-pembrolizumab therapy predicts long-term survival in patients with advanced urothelial carcinoma

Pembrolizumab has been widely used to treat advanced urothelial carcinoma that has progressed after first-line platinum-based chemotherapy. Because its clinical benefits are limited, biomarkers that can predict a good response to pembrolizumab are required. The prognostic nutritional index (PNI), calculated using the serum albumin level and peripheral lymphocyte count, has been evaluated as a predictive biomarker in cancer immunotherapy. The present study investigated the application of PNI as a predictive biomarker for pembrolizumab response in patients with advanced urothelial cancer. A retrospective study was conducted on 34 patients treated with pembrolizumab at Shiga University of Medical Science Hospital between January 2018 and July 2022. The posttreatment PNI (post-PNI) was calculated within 2 months of starting pembrolizumab. The present study investigated the association between post-PNI and objective response, overall survival (OS) and progression-free survival (PFS). The patient cohort was stratified into two categories, high and low post-PNI groups, with a cutoff value of post-PNI at 40. The higher post-PNI group demonstrated a better disease control rate than the lower post-PNI group (complete response + partial response + stable disease, 75 vs. 21%, P=0.004). Regarding median OS, the higher post-PNI group exhibited a significantly longer survival time than the lower post-PNI group (23.1 vs. 2.9 months, P<0.001). Similarly, the higher post-PNI group exhibited a significantly longer PFS than the lower post-PNI group (10.2 vs.1.9 months, P<0.001). Multivariate analysis showed that a higher post-PNI value was an independent predictor for OS (hazard ratio, 0.04; 95% confidence interval, 0.01-0.14; P<0.001) and PFS (hazard ratio, 0.12; 95% confidence interval, 0.04-0.35; P<0.001). The present study indicated that the post-PNI was a predictor of favorable clinical outcomes in patients treated with pembrolizumab for advanced urothelial carcinoma

Reactions of stock returns to Moody\u27s bond rating changes: An event study on the stock market efficiency in Southeast Asian emerging markets: Thailand, Indonesia and Philippines

Conventional wisdom has given us the idea that markets are efficient as security prices and returns reflect all relevant information hence the efficient market hypothesis. However, recent studies on market efficiency show the contrary. Studies by Hand, et al. (1992), Taib, et al. (2006) and Micu, et al. (2006), found that when event such as rating changes occur, it results to abnormal return. Moreover, this study reveals that stock market reacts significantly to such changes, which means that it contains information that are not reflected in the prices (and returns). Along with this finding, our research examined how an emerging economy\u27s stock market reacts to rating changes through event study